After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Introduction The development of an effective vaccine to protect against HIV is a longstanding
global health need complicated by challenges inherent to HIV biology and to the execution …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX …

Antiretroviral drug therapy (ART) effectively suppresses replication of both the
immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon …

Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …

A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)–HIV and
gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution …

The partial efficacy reported in the RV144 HIV vaccine trial in 2009 has driven the HIV
vaccine field to define correlates of risk associated with HIV-1 acquisition and connect these …

Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …

RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …

HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus
across mucosal epithelium to infect CD4+ T cells. Although broadly neutralizing antibodies …